Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
Abstract Background The efficacy of definite for non‐small‐cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second‐ and third‐generation T...
Salvato in:
| Autori principali: | , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2023-08-01
|
| Serie: | Cancer Medicine |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/cam4.6229 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|